Table 2 Summary of ADCC data for CLL... | American Society of Hematology

Table 2

Summary of ADCC data for CLL patient samples, n = 8

Patient ID	Maximal lysis, %		ED_{50, pM}
Patient ID	HCD122	Rituximab	HCD122	Rituximab
C4	46.35	20.15	5.12	127.64
C21	32.90	32.80	14.86	272.68
C22	46.65	31.08	3.24	62.08
C27	79.87	56.04	0.99	71.54
C30	37.60	21.33	8.87	170.34
C31	63.40	27.27	3.23	64.59
C32	56.92	49.97	3.14	16.58
C33 (1)*	27.71	12.33	49.53	473.28
C33 (2)*	48.57	28.63	37.85	141.03
Average	48.89	31.07	14.09	155.53
	P = .001		P = .010

Patient ID	Maximal lysis, %		ED_{50, pM}
Patient ID	HCD122	Rituximab	HCD122	Rituximab
C4	46.35	20.15	5.12	127.64
C21	32.90	32.80	14.86	272.68
C22	46.65	31.08	3.24	62.08
C27	79.87	56.04	0.99	71.54
C30	37.60	21.33	8.87	170.34
C31	63.40	27.27	3.23	64.59
C32	56.92	49.97	3.14	16.58
C33 (1)*	27.71	12.33	49.53	473.28
C33 (2)*	48.57	28.63	37.85	141.03
Average	48.89	31.07	14.09	155.53
	P = .001		P = .010

ADCC activity was determined for patient C33 using NK cells from 2 different donors and is therefore designated C33 (1) and C33 (2).